Marker Therapeutics: Next Major Leap in T-Cell Based Immunotherapies for Cancer
Marker Therapeutics (NASDAQ: MRKR), Inc. is a a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based …
One Response
Company has great potential, their therapy is potentially groundbreaking and extremely cost effective compared to CART therapy.
Company has great potential, their therapy is potentially groundbreaking and extremely cost effective compared to CART therapy.